Blockade of renal effects of dopamine in the dog by the DA1 antagonist SCH 23390.

Blockade of renal effects of dopamine in the dog by the DA1 antagonist SCH 23390.
复制标题

DA1 拮抗剂 SCH 23390 阻断多巴胺对狗的肾脏影响。

DOI:
10.1152/ajprenal.1985.249.2.f236
复制
发表时间:
1985
期刊:
The American journal of physiology
影响因子:
--
通讯作者:
Goldberg,LI
Goldberg,LI
中科院分区:
--
文献类型:
--
作者:
Frederickson,ED;Bradley,T;Goldberg,LI

文献摘要

被引文献

相似文献

多巴胺(DA)作用于两种受体亚型,DA 1和DA 2。本研究的目的是确定哪种亚型参与DA产生的肾血流量(RBF)和电解质排泄的增加。给予酚苄明(10 mg X kg-1 ia)和普萘洛尔(5 mg X kg-1 iv)以排除α和β肾上腺素受体介导的效应。在给予选择性DA 1拮抗剂SCH 23390或选择性DA 2拮抗剂多潘立酮之前和之后,将DA注入肾动脉。单独使用DA时,RBF增加了52 +/-7%,Na+排泄增加了35 +/-8%,K+排泄增加了35 +/-5%。输注SCH 23390(0.5 μ g X kg-1 X min-1)可完全阻断DA诱导的RBF和电解质排泄增加。静脉输注多潘立酮(1 μ g × kg-1 × min-1)不会减弱对DA的反应。SCH 23390和多潘立酮均不影响基线RBF或电解质排泄,表明在这些实验中内源性DA不活跃。总之,这些数据表明,DA增加RBF和电解质排泄的作用是对DA 1受体作用的结果。
Dopamine (DA) acts on two receptor subtypes, DA1 and DA2. The purpose of this study was to determine which subtype is involved in the increments in renal blood flow (RBF) and electrolyte excretion produced by DA. Mongrel dogs were anesthetized with pentobarbital sodium. Phenoxybenzamine (10 mg X kg-1 ia) and propranolol (5 mg X kg-1 iv) were administered to exclude effects mediated by alpha- and beta-adrenoceptors. DA was infused into the renal artery before and after administration of either the selective DA1 antagonist SCH 23390 or the selective DA2 antagonist domperidone. With DA alone, RBF increased by 52 +/- 7%, Na+ excretion increased by 35 +/- 8%, and K+ excretion increased by 35 +/- 5%. Infusion of SCH 23390 (0.5 micrograms X kg-1 X min-1) completely blocked DA-induced increase in RBF and electrolyte excretion. Intravenous infusion of domperidone (1 microgram X kg-1 X min-1) did not attenuate the responses to DA. Neither SCH 23390 nor domperidone affected base-line RBF or electrolyte excretion, suggesting that in these experiments endogenous DA was not active. In conclusion, these data indicate that the effects of DA to increase RBF and electrolyte excretion are the result of action on DA1 receptors.